NCT03619538

Brief Summary

This study analyses interest of iv nefopam in combination with paracetamol after major abdominal surgery because the effect of morphine-sparing is discussed when combined these agents.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2007

Shorter than P25 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2007

Completed
24 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 25, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 25, 2007

Completed
11.1 years until next milestone

First Submitted

Initial submission to the registry

July 25, 2018

Completed
14 days until next milestone

First Posted

Study publicly available on registry

August 8, 2018

Completed
Last Updated

December 1, 2025

Status Verified

August 1, 2018

Enrollment Period

24 days

First QC Date

July 25, 2018

Last Update Submit

November 24, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Estimate morphine consumption

    mg

    over 48 hours

Study Arms (2)

control group

PLACEBO COMPARATOR
Other: saline solution

Nefopam group

EXPERIMENTAL
Drug: Nefopam

Interventions

The nefopam group received 120 mg nefopam (Acupan, Pharmbio, France) by continuous iv infusion over the study period (48h)

Nefopam group

The Control group received 120 mg placebo infusion (saline solution) by continuous iv infusion over the study period (48h).

control group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patient with a score ASA between I and III
  • Patient scheduled for elective major abdominal surgery (by laparotomy) for cancer or diverticulosis
  • Patient that signed the consent form

You may not qualify if:

  • \- Patient treated in emergency situation
  • Patient with chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis)
  • Patient that needs a surgery for restoration of continuity
  • Patient pregnant, breastfeeding, or during periods of genital activity using no contraception.
  • Patient with contraindications to nefopam, morphine, or paracetamol
  • Patient with chronic obstructive pulmonary disease, renal or severe hepatic impairment
  • Patient under analgesics treatment
  • Patient who participated in a clinical study in the previous 6 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Cuvillon P, Zoric L, Demattei C, Alonso S, Casano F, L'hermite J, Ripart J, Lefrant JY, Muller L. Opioid-sparing effect of nefopam in combination with paracetamol after major abdominal surgery: a randomized double-blind study. Minerva Anestesiol. 2017 Sep;83(9):914-920. doi: 10.23736/S0375-9393.17.11508-7. Epub 2017 Feb 13.

MeSH Terms

Conditions

Colonic NeoplasmsDiverticulosis, Colonic

Interventions

NefopamSaline Solution

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Intervention Hierarchy (Ancestors)

OxazocinesAzocinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Jacques RIPART, Dr

    Nîmes University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 25, 2018

First Posted

August 8, 2018

Study Start

June 1, 2007

Primary Completion

June 25, 2007

Study Completion

June 25, 2007

Last Updated

December 1, 2025

Record last verified: 2018-08